Institutional Investors

Tau – Vote No On Giveaway Sale

Just received a rather disappointing RNS from TAU.

Q2 hedge fund letters, conference, scoops etc

To summarize they hold about $1m Cash and Stopharm – a Kazakhstan pharmacy.

They are suspended as they couldnt publish their results – being unable to value Stopharm.

The recent RNS has stated the offer is $1.1m post costs.  Giving a total value of Tau of about $2.1m or 4.2c per share, maybe a touch less.  I paid . . .


This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here

If you are subscribed and having an account error please clear cache and then cookies if that does not work email and we will get back to you as quick as humanly possible

Subscribe to our mailing list

* indicates required

Opt out of occasional 3rd party offers